Total Payments
$356,321
2024 Payments
$32,304
Companies
30
Transactions
393
Medicare Patients
872
Medicare Billing
$147,556
Payment Breakdown by Category
Consulting$256,845 (72.1%)
Travel$43,059 (12.1%)
Other$39,925 (11.2%)
Food & Beverage$8,515 (2.4%)
Research$7,958 (2.2%)
Education$19.81 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $256,845 | 83 | 72.1% |
| Travel and Lodging | $43,059 | 149 | 12.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $33,925 | 5 | 9.5% |
| Food and Beverage | $8,515 | 140 | 2.4% |
| Unspecified | $7,958 | 13 | 2.2% |
| Honoraria | $6,000 | 2 | 1.7% |
| Education | $19.81 | 1 | 0.0% |
Payments by Type
General
$348,363
380 transactions
Research
$7,958
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $116,811 | 120 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $85,907 | 103 | $0 (2024) |
| Advanced Accelerator Applications | $26,287 | 14 | $0 (2021) |
| Clovis Oncology, Inc. | $15,028 | 3 | $0 (2020) |
| Janssen Scientific Affairs, LLC | $14,693 | 21 | $0 (2024) |
| PROGENICS PHARMACEUTICALS, INC. | $10,044 | 3 | $0 (2024) |
| Seattle Genetics, Inc. | $9,938 | 17 | $0 (2019) |
| Janssen Biotech, Inc. | $8,986 | 10 | $0 (2023) |
| EMD Serono, Inc. | $8,092 | 10 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $7,473 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32,304 | 51 | PROGENICS PHARMACEUTICALS, INC. ($10,044) |
| 2023 | $36,663 | 46 | Bayer Healthcare Pharmaceuticals Inc. ($11,931) |
| 2022 | $35,976 | 33 | Bayer HealthCare Pharmaceuticals Inc. ($18,777) |
| 2021 | $43,730 | 29 | Advanced Accelerator Applications ($15,245) |
| 2020 | $33,314 | 20 | Merck Sharp & Dohme Corporation ($9,718) |
| 2019 | $68,213 | 82 | Bayer HealthCare Pharmaceuticals Inc. ($17,289) |
| 2018 | $64,216 | 83 | Merck Sharp & Dohme Corporation ($35,514) |
| 2017 | $41,906 | 49 | Merck Sharp & Dohme Corporation ($16,813) |
All Payment Transactions
393 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | PADCEV (Biological) | — | In-kind items and services | $3,200.00 | Research |
| Study: PADCEV CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 12/09/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $817.50 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $915.00 | General |
| 10/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Consulting Fee | Cash or cash equivalent | $4,326.00 | General |
| Category: Oncology | ||||||
| 10/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Travel and Lodging | In-kind items and services | $123.11 | General |
| Category: Oncology | ||||||
| 10/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Travel and Lodging | In-kind items and services | $65.00 | General |
| Category: Oncology | ||||||
| 10/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $63.71 | General |
| Category: Oncology | ||||||
| 10/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Travel and Lodging | In-kind items and services | $62.87 | General |
| Category: Oncology | ||||||
| 10/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 10/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $45.63 | General |
| Category: Oncology | ||||||
| 10/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Oncology | ||||||
| 10/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Travel and Lodging | In-kind items and services | $226.86 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $138.71 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $260.10 | General |
| Category: Oncology | ||||||
| 09/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $343.47 | General |
| Category: Oncology | ||||||
| 09/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $293.20 | General |
| Category: Oncology | ||||||
| 09/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $241.20 | General |
| Category: Oncology | ||||||
| 09/22/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 09/12/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Travel and Lodging | In-kind items and services | $26.00 | General |
| 09/11/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Travel and Lodging | In-kind items and services | $7,587.60 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 09/11/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Travel and Lodging | In-kind items and services | $39.40 | General |
| 09/11/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Travel and Lodging | In-kind items and services | $39.40 | General |
| 09/11/2024 | LANTHEUS MEDICAL IMAGING, INC. | — | Travel and Lodging | In-kind items and services | $30.60 | General |
| 09/11/2024 | PROGENICS PHARMACEUTICALS, INC. | PYLARIFY (Drug) | Travel and Lodging | In-kind items and services | $26.00 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PADCEV CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| PCYC-1128-CA | Pharmacyclics LLC, An AbbVie Company | $2,258 | 2 |
| A Phase 2 Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) in Subjects With HER2 Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma | Seagen Inc. | $1,156 | 6 |
| AMG 509_Prostate Cancer_20180146. | Amgen Inc. | $635.14 | 1 |
| TUKYSA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| Phase 1 study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients wit | Amgen Inc. | $247.91 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RAMUCIRUMAB PLUS DOCETAXEL VERSUS PLACEBO PLUS DOCETAXEL IN PATIENTS WITH LOCALLY ADVANCED OR UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA WHO PROGRESSED ON OR AFTER PLATINUM-BASED THERAPY | Eli Lilly and Company | $131.40 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 170 | 286 | $93,470 | $27,120 |
| 2022 | 5 | 214 | 387 | $104,858 | $37,136 |
| 2021 | 7 | 282 | 531 | $142,730 | $51,568 |
| 2020 | 3 | 206 | 382 | $140,060 | $31,732 |
Total Patients
872
Total Services
1,586
Medicare Billing
$147,556
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 86 | 166 | $62,426 | $18,756 | 30.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 60 | $15,858 | $4,210 | 26.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $11,739 | $3,190 | 27.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 20 | 37 | $3,448 | $965.43 | 28.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 88 | 169 | $52,323 | $20,265 | 38.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 52 | 83 | $18,144 | $6,080 | 33.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 28 | 28 | $13,231 | $4,309 | 32.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 34 | $9,663 | $2,991 | 31.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $6,061 | $1,901 | 31.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 22 | 60 | $5,436 | $1,591 | 29.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 116 | 260 | $78,624 | $30,173 | 38.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 79 | 126 | $26,977 | $9,567 | 35.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 25 | 25 | $11,473 | $3,769 | 32.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 34 | $9,595 | $3,017 | 31.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 12 | $6,578 | $2,065 | 31.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 12 | 27 | $5,287 | $1,667 | 31.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 26 | 47 | $4,197 | $1,311 | 31.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 87 | 185 | $72,209 | $16,865 | 23.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 87 | 165 | $48,215 | $10,136 | 21.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 32 | 32 | $19,637 | $4,731 | 24.1% |
About Evan Yu
Evan Yu is a Medical Oncology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043390016.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Evan Yu has received a total of $356,321 in payments from pharmaceutical and medical device companies, with $32,304 received in 2024. These payments were reported across 393 transactions from 30 companies. The most common payment nature is "Consulting Fee" ($256,845).
As a Medicare-enrolled provider, Yu has provided services to 872 Medicare beneficiaries, totaling 1,586 services with total Medicare billing of $147,556. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Internal Medicine
- Location Seattle, WA
- Active Since 10/16/2006
- Last Updated 11/21/2012
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1043390016
Products in Payments
- Nubeqa (Drug) $48,578
- Xofigo (Drug) $27,274
- Rubraca (Drug) $15,028
- KEYTRUDA (Biological) $13,495
- Erleada (Drug) $10,434
- PYLARIFY (Drug) $10,044
- ERLEADA (Drug) $8,693
- Non-Covered (Drug) $8,301
- Bavencio (Biological) $8,092
- ELIGARD (Drug) $5,685
- NO PRODUCT DISCUSSED (Drug) $4,835
- LUTATHERA (Drug) $4,056
- Cabometyx (Drug) $3,960
- PADCEV (Biological) $3,200
- IMFINZI (Drug) $2,786
- Ibrutinib (Drug) $2,258
- ZYTIGA (Drug) $2,217
- FYARRO (Drug) $1,500
- PROVENGE (Drug) $1,405
- LYNPARZA (Biological) $765.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Seattle
Bart Scott
Medical Oncology — Payments: $1.5M
Medical Oncology $1.5M
Petros Grivas, M.d, M.D
Medical Oncology — Payments: $683,103
Medical Oncology $683,103
Gary Lyman, Md, MD
Medical Oncology — Payments: $176,021
Medical Oncology $176,021
Jerald Radich, Md, MD
Medical Oncology — Payments: $171,817
Medical Oncology $171,817
David Maloney
Medical Oncology — Payments: $167,323
Medical Oncology $167,323
Laura Chow, Md, MD
Medical Oncology — Payments: $156,359
Medical Oncology $156,359